



Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences

November 8, 2022

WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 8, 2022-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that members of the management team will participate in fireside chats at the following investor conferences:

- Stifel Healthcare Conference on Tuesday, November 15, 2022 at 10:55 AM ET in New York, NY
- Jefferies London Healthcare Conference on Thursday, November 17, 2022 at 8:30 AM ET / 1:30 PM GMT in London, United Kingdom
- Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022 at 4:00 PM ET in New York, NY

Live webcasts will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at <https://investors.deciphera.com/events-presentations>. All webcast replays will be archived on the Company's website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera's switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20221108005236/en/): <https://www.businesswire.com/news/home/20221108005236/en/>

Investor Relations:

Maghan Meyers
Argot Partners
Deciphera@argotpartners.com
212-600-1902

Media:

David Rosen
Argot Partners
david.rosen@argotpartners.com
212-600-1902

Source: Deciphera Pharmaceuticals, Inc.